Evidence map›Paper›PMID 36426935›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

E6020, a TLR4 Agonist Adjuvant, Enhances Both Antibody Titers and Isotype Switching in Response to Immunization with Hapten-Protein Antigens and Is Diminished in Mice with TLR4 Signaling Insufficiency.

Archana Gopalakrishnan, Katharina Richard, Rezwanul Wahid, Regina Harley, Marcelo B Sztein, Lynn D Hawkins, Stefanie N Vogel

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Archana GopalakrishnanDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0001-6145-5146
Katharina RichardDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0003-0939-2103
Rezwanul WahidCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD; and.ORCID 0000-0002-5623-1903
Regina HarleyCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD; and.ORCID 0000-0002-7648-6030
Marcelo B SzteinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD; and.ORCID 0000-0001-8282-860X
Lynn D HawkinsG2D2, Eisai Inc., Cambridge, MA.ORCID 0000-0003-1484-5250
Stefanie N VogelDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD.ORCID 0000-0001-8244-2555
University of Maryland, Baltimore · USEisai (United States) · US

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2009 to 2018
$27.8M
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni diseaseU19AI142725 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2019 to 2023
$12.5M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung InjuryR01AI125215 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLANCO, JORGE C, VOGEL, STEFANIE N. · 2017 to 2021
$2.7M
Macrophage differentiation and disease outcome in influenza infectionR01AI123371 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI VOGEL, STEFANIE N. · 2017 to 2021
$2.7M
NIAID NIH HHS R01 AI036525NIAID NIH HHS R01 AI123371NIAID NIH HHS R01 AI125215NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI142725
6 · The paper itself

Abstract

The mechanisms by which TLR4-based adjuvants enhance immunogenicity are not fully understood. We have taken advantage of a novel knock-in mouse strain that homozygously expresses two single-nucleotide polymorphisms (SNPs) that are homologous to human TLR4 (rs4986790 and rs4986791) and have been associated with LPS hyporesponsiveness in vivo and in vitro. TLR4-SNP (coexpressing mutations D298G/N397I in TLR4) mice that recapitulate the human phenotype were compared with wild-type (WT) mice for their hapten-specific Ab responses after immunization with hapten 4-hydroxy-3-nitrophenyl acetyl (NP) NP-Ficoll or NP-OVA in the absence or presence of a water-soluble TLR4 analog adjuvant, E6020. IgM and IgG anti-NP responses were comparable in WT and TLR4-SNP mice after immunization with either NP-Ficoll or NP-OVA only. E6020 significantly yet transiently improved the IgM and IgG anti-NP responses of both WT and TLR4-SNP mice to NP-Ficoll (T-independent), with modestly enhanced Ab production in WT mice. In contrast, T-dependent (NP-OVA), adjuvant-enhanced responses showed sustained elevation of NP-specific Ab titers in WT mice, intermediate responses in TLR4-SNP mice, and negligible enhancement in TLR4-/- mice. E6020-enhanced early humoral responses in WT and TLR4-SNP mice to NP-OVA favored an IgG1 response. After a second immunization, however, the immune responses of TLR4-SNP mice remained IgG1 dominant, whereas WT mice reimmunized with NP-OVA and E6020 exhibited increased anti-NP IgG2c titers and a sustained increase in the IgG1 and IgG2c production by splenocytes. These findings indicate that E6020 increases and sustains Ab titers and promotes isotype class switching, as evidenced by reduced titers and IgG1-dominant immune responses in mice with TLR4 insufficiency.

Indexed as

Immunoglobulin Class SwitchingToll-Like Receptor 4Adjuvants, ImmunologicAnimalsFicollHaptensHumansImmunizationImmunoglobulin GImmunoglobulin MMicePhospholipidsAdjuvants, ImmunologicER-804053FicollHaptensImmunoglobulin GImmunoglobulin MPhospholipidsTLR4 protein, humanTlr4 protein, mouseToll-Like Receptor 4

Identifiers

PMID36426935
PMCPMC9643654
OpenAlexW4302761398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.